Elcatonin Side Effects: Safety Signals and Warnings
Elcatonin safety concerns are compound-specific. The main listed side effects are Nausea, Facial flushing, and Injection site reactions. The main warning signals are Allergic reactions including anaphylaxis reported (rare), Not widely available outside Japan and some Asian countries, and Long-term cancer risk concerns similar to other calcitonins (theoretical).
Direct Answer
Elcatonin (eel calcitonin) is approved in Japan and Russia for osteoporosis with some Phase 3 data supporting antiresorptive effects and pain relief, but lacks FDA approval and the evidence base is substantially thinner than salmon calcitonin. It is a regional approval with limited international evidence. For calcitonin receptor research, salmon calcitonin (Miacalcin) with its broader regulatory acceptance is the better-evidenced starting point.
- Evidence grade
- Level B
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Osteoporosis management (Japan/Russia context), calcitonin receptor pharmacology research
Reported Side Effects
- Nausea
- Facial flushing
- Injection site reactions
- Dizziness
- Rash
- Loss of appetite
Warnings
- Allergic reactions including anaphylaxis reported (rare)
- Not widely available outside Japan and some Asian countries
- Long-term cancer risk concerns similar to other calcitonins (theoretical)
- Escape phenomenon may limit long-term bone density benefits
Known or Plausible Interactions
- Bisphosphonates (may be used sequentially)
- Calcium supplements (concomitant use recommended)
- Vitamin D (concomitant supplementation recommended)
Regulatory Context
Approved in Japan for osteoporosis and bone pain. Not FDA-approved in the United States. Available by prescription in Japan and several Asian countries. Marketed as Elcitonin by Asahi Kasei Pharma.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Bone Pain Relief (Level B), Bone Density Maintenance (Level B), and Bone Turnover Marker Reduction (Level B) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Elcatonin Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/elcatonin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.